Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Bill to Make Cost-Effective Biological Drug Alternatives More Widely Available Heads to Governor

Trenton, NJ, June 28, 2015 ― Legislation sponsored by Assembly Democrats Pamela Lampitt, Herb Conaway, Jr., M.D., Daniel Benson, Shavonda Sumter, Angel Fuentes and Nancy Pinkin to make it easier for consumers to obtain more cost-effective, “generic” versions of biological medicines used to treat conditions such as rheumatoid arthritis, anemia, psoriasis and various forms of cancer was approved 75-0 Thursday by the Assembly, giving it final legislative approval.

The bill now goes to the governor.

“The FDA has created a safe pathway to make alternative biological medicines more readily available on the market,” said Lampitt (D-Camden, Burlington). “If there is a more cost-effective option to treat and cure various illnesses, then by all means we should be helping patients pursue it.”

“Substitution of these biologically similar products for their name-brand counterparts at the pharmacy level is expected to reduce cost by increasing competition,” said Conaway (D-Burlington). “Ultimately, this will allow more patients to access treatments.”

While New Jersey has allowed chemically-synthesized generic drugs to be substituted for brand-name prescriptions for quite some time because the active ingredients are identical to their brand-name counterparts, biological medicines, on the other hand, are manufactured through biotechnology using living organisms and are much more complex than traditional, chemically-synthesized drugs.

However, changes created under the federal “Patient Protection and Affordable Care Act” made it easier for biosimilar biological products to gain licensure from the federal Food and Drug Administration (FDA). Over the past eighteen months, approximately 23 states have considered legislation establishing state standards for the substitution of biosimilar prescription products and as of December 31, 2014, eight states had enacted statutes.

The bill (A2477) would add New Jersey to that list, allowing for the substitution of biosimilar products by pharmacists, provided the conditions set forth in the bill are met.

“For lower income families or seniors on a fixed-income who might not be able to afford the name-brand version of these innovative medicines, this can be a game changer,” said Benson (D-Mercer, Middlesex). “This bill would provide more people with greater access to life-altering treatments.”

“Certain biological drugs on the market can drastically improve a person’s outcome and should be made more readily accessible,” said Sumter (D-Bergen, Passaic). “Simply put, biosimilar medicines cost less and can save lives.”

Specifically, the bill directs the State Board of Pharmacy to maintain a link on the board’s website to the current list of all biological products determined by the FDA to be interchangeable. A pharmacist would be able to substitute such a product for a prescribed biological product if the prescriber has not indicated that there be no substitution.

A pharmacist, who dispenses a biological product would have to communicate the name of the product and the manufacturer to the prescriber within five business days after dispensing unless there is no biological product that has been determined by the FDA to be either interchangeable with the product described; or a refill prescription is not changed from the product dispensed on the prior filling of the prescription.

“Biological medicines can offer a new lease on life for someone struggling with certain cancers or debilitating conditions like rheumatoid arthritis, but not everyone can afford them,” said Fuentes (D-Camden, Gloucester). “This would create greater access to them for those in need.”

“For people with many rare conditions, biological medicines can dramatically enhance their quality of life, but they come at a significant price,” said Pinkin (D-Middlesex). “This bill would help change all that by providing a more cost-effective alternative.”

Under the bill, a pharmacist who substitutes a biological product would have to record, on the prescription label and record of dispensing, the product name and manufacturer of the biological product dispensed, followed by the words: “Substituted for” and the name of the biological product for which the prescription was written. The same recordkeeping requirements as apply to the dispensing of drugs would apply to the dispensing of biological products.

The bill provides immunity from liability for a pharmacist who makes such substitutions in compliance with the bill to the same extent that immunity would be provided for dispensing the prescribed biological reference product.